L&K Biomed Ltd. (KOSDAQ:156100)

L&K Biomed Statistics

Total Valuation

L&K Biomed has a market cap or net worth of KRW 276.69 billion. The enterprise value is 282.42 billion.

Market Cap	276.69B
Enterprise Value	282.42B

Important Dates

The next estimated earnings date is Thursday, March 12, 2026.

Earnings Date	Mar 12, 2026
Ex-Dividend Date	n/a

Share Statistics

L&K Biomed has 21.79 million shares outstanding. The number of shares has increased by 8.24% in one year.

Current Share Class	21.79M
Shares Outstanding	21.79M
Shares Change (YoY)	+8.24%
Shares Change (QoQ)	+1.56%
Owned by Insiders (%)	12.18%
Owned by Institutions (%)	0.37%
Float	19.13M

Valuation Ratios

The trailing PE ratio is 47.84.

PE Ratio	47.84
Forward PE	n/a
PS Ratio	6.86
PB Ratio	6.49
P/TBV Ratio	5.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 53.81, with an EV/FCF ratio of -21.14.

EV / Earnings	48.37
EV / Sales	7.00
EV / EBITDA	53.81
EV / EBIT	113.73
EV / FCF	-21.14

Financial Position

The company has a current ratio of 1.86, with a Debt / Equity ratio of 0.52.

Current Ratio	1.86
Quick Ratio	0.86
Debt / Equity	0.52
Debt / EBITDA	4.23
Debt / FCF	-1.66
Interest Coverage	0.75

Financial Efficiency

Return on equity (ROE) is 14.33% and return on invested capital (ROIC) is 2.59%.

Return on Equity (ROE)	14.33%
Return on Assets (ROA)	1.93%
Return on Invested Capital (ROIC)	2.59%
Return on Capital Employed (ROCE)	5.00%
Revenue Per Employee	399.36M
Profits Per Employee	57.81M
Employee Count	60
Asset Turnover	0.50
Inventory Turnover	0.28

Taxes

In the past 12 months, L&K Biomed has paid 406.29 million in taxes.

Income Tax	406.29M
Effective Tax Rate	6.98%

Stock Price Statistics

The stock price has increased by +71.47% in the last 52 weeks. The beta is 0.73, so L&K Biomed's price volatility has been lower than the market average.

Beta (5Y)	0.73
52-Week Price Change	+71.47%
50-Day Moving Average	12,401.40
200-Day Moving Average	8,519.25
Relative Strength Index (RSI)	46.59
Average Volume (20 Days)	376,577

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, L&K Biomed had revenue of KRW 40.33 billion and earned 5.84 billion in profits. Earnings per share was 265.47.

Revenue	40.33B
Gross Profit	33.22B
Operating Income	2.48B
Pretax Income	5.82B
Net Income	5.84B
EBITDA	5.25B
EBIT	2.48B
Earnings Per Share (EPS)	265.47

Balance Sheet

The company has 10.41 billion in cash and 22.21 billion in debt, with a net cash position of -11.80 billion or -541.68 per share.

Cash & Cash Equivalents	10.41B
Total Debt	22.21B
Net Cash	-11.80B
Net Cash Per Share	-541.68
Equity (Book Value)	42.64B
Book Value Per Share	2,346.93
Working Capital	27.94B

Cash Flow

In the last 12 months, operating cash flow was -10.82 billion and capital expenditures -2.54 billion, giving a free cash flow of -13.36 billion.

Operating Cash Flow	-10.82B
Capital Expenditures	-2.54B
Free Cash Flow	-13.36B
FCF Per Share	-613.26

Margins

Gross margin is 82.36%, with operating and profit margins of 6.16% and 14.48%.

Gross Margin	82.36%
Operating Margin	6.16%
Pretax Margin	14.43%
Profit Margin	14.48%
EBITDA Margin	13.01%
EBIT Margin	6.16%
FCF Margin	n/a

Dividends & Yields

L&K Biomed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.24%
Shareholder Yield	-8.24%
Earnings Yield	2.11%
FCF Yield	-4.83%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

L&K Biomed has an Altman Z-Score of 2.67 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.67
Piotroski F-Score	5